1. Home
  2. ATAI vs NOTE Comparison

ATAI vs NOTE Comparison

Compare ATAI & NOTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATAI
  • NOTE
  • Stock Information
  • Founded
  • ATAI 2018
  • NOTE 2013
  • Country
  • ATAI Germany
  • NOTE United States
  • Employees
  • ATAI N/A
  • NOTE N/A
  • Industry
  • ATAI Biotechnology: Pharmaceutical Preparations
  • NOTE EDP Services
  • Sector
  • ATAI Health Care
  • NOTE Technology
  • Exchange
  • ATAI Nasdaq
  • NOTE Nasdaq
  • Market Cap
  • ATAI 444.7M
  • NOTE 83.1M
  • IPO Year
  • ATAI 2021
  • NOTE N/A
  • Fundamental
  • Price
  • ATAI $4.61
  • NOTE $4.40
  • Analyst Decision
  • ATAI Strong Buy
  • NOTE Strong Buy
  • Analyst Count
  • ATAI 3
  • NOTE 4
  • Target Price
  • ATAI $13.33
  • NOTE $29.25
  • AVG Volume (30 Days)
  • ATAI 4.7M
  • NOTE 323.1K
  • Earning Date
  • ATAI 11-12-2025
  • NOTE 11-11-2025
  • Dividend Yield
  • ATAI N/A
  • NOTE N/A
  • EPS Growth
  • ATAI N/A
  • NOTE N/A
  • EPS
  • ATAI N/A
  • NOTE N/A
  • Revenue
  • ATAI $2,309,000.00
  • NOTE $109,683,000.00
  • Revenue This Year
  • ATAI $712.99
  • NOTE N/A
  • Revenue Next Year
  • ATAI N/A
  • NOTE $42.27
  • P/E Ratio
  • ATAI N/A
  • NOTE N/A
  • Revenue Growth
  • ATAI 510.85
  • NOTE N/A
  • 52 Week Low
  • ATAI $1.03
  • NOTE $3.80
  • 52 Week High
  • ATAI $5.34
  • NOTE $24.36
  • Technical
  • Relative Strength Index (RSI)
  • ATAI 57.88
  • NOTE 35.94
  • Support Level
  • ATAI $4.50
  • NOTE $4.19
  • Resistance Level
  • ATAI $4.75
  • NOTE $5.48
  • Average True Range (ATR)
  • ATAI 0.28
  • NOTE 0.53
  • MACD
  • ATAI -0.04
  • NOTE 0.05
  • Stochastic Oscillator
  • ATAI 50.33
  • NOTE 33.52

About ATAI ATAI Life Sciences N.V.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.

About NOTE FiscalNote Holdings Inc.

FiscalNote Holdings Inc is a provider of world-wide policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With its analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.

Share on Social Networks: